Promising ARDS drug trial pulled before it even started
NCT ID NCT03017547
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to test whether IC14, a drug that blocks a key inflammatory signal, could help people with acute respiratory distress syndrome (ARDS). The plan was to give IC14 or a placebo to about 100 ICU patients and see if it reduced time on a ventilator. However, the trial was withdrawn before enrolling anyone, so no data was collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IC14 (a monoclonal antibody that blocks CD14 signaling)
- What this could lead to
- If it had worked, this could have pointed toward a new treatment for ARDS by reducing inflammation in the lungs.
- What could go wrong
- The trial was withdrawn before any patients were enrolled, so no results are available. Early-phase studies often fail to show benefit in larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY DISTRESS SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Lung-Opening maneuver change a key injury marker in ARDS?
- Could simply sitting up ease breathing in severe lung failure?
- Could lung fluid proteins reveal a new way to track severe lung injury?
- Could a spirometer test guide breathing support in respiratory failure?
- Which ventilator setting saves more lungs? a Head-to-Head test
- Can a single antibody turn down the immune storm in ARDS?